ANTIVIRAL DRUGS MARKET ANALYSIS

Antiviral Drugs Market, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, and Others), By Type (Branded and Generics), By Application (HIV, Hepatitis, Herpes, Influenza, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2024
Code : CMI4912
Pages :189
Formats :
Excel and PDF
Industry : Medical Devices

Market Challenge – High Cost of Hepatitis Drugs

High cost of hepatitis drugs is a major barrier for many patients to receive treatment for this disease. The U.S. Food and Drug Administration approved direct-acting antiviral medications for the treatment of hepatitis C disease.

The high cost drugs for hepatitis C –

Harvoni costs US$ 94,500 for a 12-week treatment

Mavyret costs US$ 39,600 for a 12-week treatment

Technivie costs US$ 76,653 for a 12-week treatment

Such high cost treatment is a major restraining factor for the antiviral drugs market.

Market Opportunity – Increasing Focus on Combination Therapies

Increasing focus on combination therapies is indeed a great opportunity for growth in the global antiviral drugs market. As researchers gain a deeper understanding of viral biology and mechanisms of drug resistance, combination therapies are seen as a more effective clinical strategy compared to monotherapies. Instead of targeting a single viral protein or mechanism, combinations can act on multiple viral lifecycle stages or pathways simultaneously. This makes the development of resistance much more challenging for the virus.